Eli Lilly's Lepodisiran Achieves 94.8% Reduction in Genetic Cholesterol in Phase 2 Trial

The injectable drug, targeting lipoprotein(a), moves to Phase 3 trials to assess its impact on cardiovascular events, with no serious adverse effects reported.

Lepodisiran, an experimental drug by Eli Lilly, reduced lipoprotein(a) levels by 93.9% after six months and 94.8% after one year with a second dose in Phase 2 trials.
The drug uses RNA-targeting technology to prevent the production of lipoprotein(a), a genetic cholesterol linked to heart disease and strokes.
Phase 2 trials involving 320 participants reported no serious adverse events, marking a significant step in the drug's development.
Lepodisiran has now progressed to Phase 3 trials to determine if lowering lipoprotein(a) reduces cardiovascular events, with patient enrollment ongoing and expected to conclude this year.
Other pharmaceutical companies, including Amgen, Novartis, and Silence Therapeutics, are also developing treatments for lipoprotein(a), reflecting a competitive landscape in this field.